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Background
OX40, a TNFRSF member, is a co-stimulatory molecule
expressed on antigen experienced effector T (Teff) and
regulatory T (Treg) cells, including infiltrating cells in
mouse and human tumors. Activation of OX40 by ago-
nistic antibodies is hypothesized to promote anti-tumor
immunity by enhancing Teff activation and inhibiting
Treg mediated suppression. We conducted in vitro and
in vivo preclinical studies to characterize co-stimulatory
activity, evaluate anti-tumor efficacy and identify predic-
tive and pharmacodynamic (PD) biomarkers of agonistic
anti-OX40 antibodies.
Methods
In vitro evaluation of Teff costimulation and Treg inhibi-
tion was conducted with MOXR0916, a humanized anti-
human OX40 mAb, using purified T cells from healthy
human donors. In vivo anti-tumor efficacy was studied
using PRO307205, a murine anti-mouse Ab, in multiple
established syngeneic mouse tumor models. Baseline
tumor immune environment was characterized using mul-
tiplex gene expression analysis of 93 immune related
genes. Circulating and tumor-based PD biomarkers of
PRO307205 activity were evaluated in EMT6 and JC
tumor models using flow cytometry and multiplex gene
expression assays.
Results
Engagement of OX40 by MOXR0916 in the presence of
anti-CD3 stimulation enhanced IFN-g production and
proliferation of Teff cells, and suppressed Treg cell func-
tion in naïve T cell co-cultures. Administration of
PRO307205 resulted in a spectrum of anti-tumor activity
in vivo, including durable tumor regression in the EMT6
model and modest tumor growth inhibition in the JC
model. Higher baseline expression of immune activation
markers and lower expression of immune inhibitory and
Th2 associated markers were predictive of better anti-
tumor response to PRO307205. Biomarkers of PD activ-
ity in EMT6 and JC models included reduction of Treg
cells in blood and tumors and augmentation of cytotoxic
immune function in tumors as evidenced by increase in
gene expression of IFN-g, granzymes, and perforin. PD
modulation that corresponded with differential anti-
tumor activity included sustained enhancement of CD8
T cell infiltration and expression of co-stimulatory and
memory T cell markers such as CD86, ICOS, CXCR3,
and IL7R in EMT6 tumors but not in JC tumors.
Conclusions
Our findings show that agonistic anti-OX40 Abs induce
potent T cell activation and promote anti-tumor immunity
and efficacy in preclinical systems. Biomarkers identified
in these studies may be utilized to validate mechanism of
action, inform dose finding, and guide patient selection in
MOXR0916 clinical trials.
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